Marker Therapeutics, Inc. (MRKR) — Financial statements
Income statement, balance sheet, and cash flow for Marker Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 4↓46.2% | 7↑99.1% | 3↓5.8% | 4↑183.0% | 1 | |
| Cost of Revenue | 0.00↓100.0% | 13↑29.3% | 10↓13.0% | 12↑278.4% | 3 | |
| Gross Profit | 0.00↑100.0% | -7↑3.2% | -7↑16.0% | -8↓340.1% | -2 | |
| Operating Expenses | ||||||
| R&D Expenses | 11,799,154↑87609714.3% | 13↑29.3% | 10↓13.0% | 12↓56.9% | 28 | |
| General & Administrative Expenses | 4,184,806↑98660761.3% | 4↓43.3% | 7↓34.1% | 11 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 4,184,806↑98660761.3% | 4↓43.3% | 7↓34.1% | 11↑16.1% | 10 | |
| Other Expenses | -15,983,944↓118682168.9% | -13↓29.3% | -10↑13.0% | -12 | 0.00 | |
| Operating Expenses | 16↑276.8% | 4↓43.3% | 7↓34.1% | 11↓69.8% | 38 | |
| Total Costs & Expenses | 16↓9.7% | 18↓1.0% | 18↓23.2% | 23↓42.8% | 41 | |
| Operating Results | ||||||
| Operating Income | -12↓11.9% | -11↑23.7% | -15↑26.3% | -20↑49.9% | -39 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.00↓100.0% | 3↑0.0% | 3↓11.8% | 3 | |
| EBITDA | -12↓11.9% | -11↑5.7% | -12↑30.6% | -17↑56.1% | -39 | |
| EBIT | -12↓11.9% | -11↑23.7% | -15↑26.3% | -20↑52.7% | -42 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.59↑36.0% | 0.44↓18.9% | 0.54↑117.3% | 0.25↑4252.0% | 0.01 | |
| Interest Income | 0.59↑36.0% | 0.44↓18.9% | 0.54↑117.3% | 0.25↑4252.0% | 0.01 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 2 | |
| Other Income / Expenses | 0.26↓40.8% | 0.44↓18.9% | 0.54↑3473.2% | 0.02↑100.6% | -2 | |
| Income Before Tax | -12↓14.0% | -11↑23.9% | -14↑29.0% | -20↑52.8% | -42 | |
| Income Tax Expense | -0.02↓130.3% | 0.05↑1259.3% | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -12↓13.3% | -11↑23.6% | -14↑29.0% | -20↑52.8% | -42 | |
| Net Income from Discontinued Operations | 0.00 | 0.00↓100.0% | 6↑157.2% | -10 | 0.00 | |
| Net Income | -12↓13.3% | -11↓30.3% | -8↑72.5% | -30↑28.5% | -42 | |
| Bottom-Line Net Income | -12↓13.3% | -11↑23.6% | -14↑29.0% | -20↑52.8% | -42 | |
| EPS (Basic) | -0.79↑33.6% | -1.19↑38.3% | -1.93↑46.1% | -3.58↑34.6% | -5.47 | |
| EPS (Diluted) | -0.79↑33.6% | -1.19↑38.3% | -1.93↑46.1% | -3.58↑34.6% | -5.47 | |
| Weighted Average Shares | 15↑70.5% | 9↑1.9% | 9↑5.5% | 8↑9.1% | 8 | |
| Weighted Average Diluted Shares | 15↑70.5% | 9↑1.9% | 9↑5.5% | 8↑9.1% | 8 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.